Evidence map›Paper›PMID 28856386›Full record

ArticleDer Urologe. Ausg. A2017

[Focal therapy of prostate cancer].

R Ganzer, T Franiel, J Köllermann, T Kuru, D Baumunk, A Blana, B Hadaschik, J von Hardenberg, T Henkel, K-U Köhrmann and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in Der Urologe. Ausg. A, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 14 institutions in 1 country.

R GanzerKlinik für Urologie, Asklepios Klinik Bad Tölz, Schützenstraße 15, 83646, Bad Tölz, Deutschland. r.ganzer@asklepios.com.
T FranielInstitut für Diagnostische und Interventionelle Radiologie, Universitätsklinikum Jena, Jena, Deutschland.
J KöllermannInstitut für Pathologie, Sana Klinikum Offenbach, Offenbach am Main, Deutschland.
T KuruUrologie am Ebertplatz, Köln, Deutschland.
D BaumunkUrologische Praxis Backnang, Backnang, Deutschland.
A BlanaKlinik für Urologie und Kinderurologie, Klinikum Fürth, Fürth, Deutschland.
B HadaschikKlinik für Urologie, Uroonkologie und Kinderurologie, Universität Essen, Essen, Deutschland.
J von HardenbergKlinik für Urologie, Universitätsmedizin Mannheim der Universität Heidelberg, Mannheim, Deutschland.
T HenkelUrologische Praxis Dr. Henkel & Dr. Kahmann, Berlin, Deutschland.
K-U KöhrmannKlinik für Urologie, Theresienkrankenhaus Mannheim, Mannheim, Deutschland.
U-B LiehrUniversitätsklinik für Urologie und Kinderurologie, Otto-von-Guericke-Universität Magdeburg, Magdeburg, Deutschland.
S MachtensKlinik für Urologie und Kinderurologie, Marien-Krankenhaus Bergisch Gladbach, Bergisch Gladbach, Deutschland.
A RoosenKlinik für Urologie, Augusta-Kranken-Anstalt gGmbH Bochum, Bochum, Deutschland.
G SalomonMartini-Klinik am UKE GmbH, Hamburg, Deutschland.
H-P SchlemmerAbteilung für Radiologie, Deutsches Krebsforschungszentrum, Heidelberg, Deutschland.
L SentkerUrologische Gemeinschaftspraxis, Sinsheim, Deutschland.
J WendlerUniversitätsklinik für Urologie und Kinderurologie, Otto-von-Guericke-Universität Magdeburg, Magdeburg, Deutschland.
U WitzschKlinik für Urologie und Kinderurologie, Krankenhaus Nordwest, Frankfurt/Main, Deutschland.
M SchostakUniversitätsklinik für Urologie und Kinderurologie, Otto-von-Guericke-Universität Magdeburg, Magdeburg, Deutschland.
Otto-von-Guericke University Magdeburg · DEAugusta-Kranken-Anstalt · DEFederal Highway Research Institute · DEFriedrich-Ebert-Krankenhaus · DEGerman Cancer Research Center · DEHenkel (Germany) · DEJena University Hospital · DEKlinikum Fürth · DEKlinik und Poliklinik für Urologie · DEKrankenhaus Nordwest · DEPraxis für Humangenetik · DESana Klinikum Offenbach · DEUniversity Hospital Heidelberg · DEUniversity Medical Center Hamburg-Eppendorf · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The target of focal therapy (FT) in prostate cancer (PC) is partial treatment of the prostate aiming at preserving surrounding anatomical structures. The intention is to minimize typical side effects of radical treatment options combined with local tumor control. Numerous established and new technologies are used. Results of published studies showed a good safety profile, few side effects and good preservation of functional results. Oncologic long-term data are lacking so far. Photodynamic therapy (PDT) is the only technology that has been studied in a published prospective randomized trial. The FT is challenged by the multifocality of PC; therefore, the quality of prostate biopsy, histopathological assessment as well as imaging are of paramount importance. Multiparametric magnetic resonance imaging (MRI) has gained increasing importance. The FT is experimental and should only be offered within clinical trials.

Indexed as

BiopsyBrachytherapyCryotherapyDisease ProgressionEndosonographyHigh-Intensity Focused Ultrasound AblationHumansLaser TherapyMagnetic Resonance ImagingMaleNeoplasm GradingNeoplasm StagingPhotochemotherapyPrognosisProstate-Specific AntigenProstatic NeoplasmsProstate-Specific AntigenCryotherapyHigh intensity focused ultrasound (HIFU)Irreversible electroporationMultiparametric magnetic resonance imagingProstatic neoplasms

Identifiers

PMID28856386
OpenAlexW2127744229

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.